lodoxamide tromethamine (Alomide)

09/01/2000 - "Our study suggests that alomide is a safe and effective drug in the treatment of allergic conjunctivitis."
01/01/2001 - "The ocular status of each patient has been evaluated with a score: the intensity of each symptom and sign has been graded between 1-3. In all cases, the use of Alomide induced the improvement of the typical symptoms and signs of the allergic conjunctivitis. "
10/01/1998 - "Lodoxamide tromethamine and N-acetyl-aspartyl glutamic acid (NAAGA) are mast cell stabilisers, both of which have been shown to be effective in the treatment of allergic conjunctivitis. "
06/01/1999 - "A double-masked, randomized, placebo-controlled study was conducted to evaluate the effectiveness of lodoxamide tromethamine 0.1% eyedrops in preventing inflammatory cell accumulation in the tear fluid of patients with vernal conjunctivitis. "
01/01/2001 - "Evaluating the efficiency and safety of Alomide (lodoxamide 01.%) in the treatment of allergic conjunctivitis. "

09/01/1995 - "Topically applied lodoxamide tromethamine 0.1% is useful in the treatment of superior limbic keratoconjunctivitis. "
09/01/1995 - "We studied the efficacy of topically applied lodoxamide tromethamine 0.1% in the treatment of superior limbic keratoconjunctivitis. "
09/01/1995 - "Lodoxamide tromethamine treatment for superior limbic keratoconjunctivitis."
07/01/1998 - "Clinical studies carried out in 170 patients demonstrated a high efficacy of alomide in the treatment of subacute and chronic pollenosis conjunctivitis, spring keratoconjunctivitis, multiple and toxic allergic keratitis, and other allergic conjunctivities. "
07/01/1998 - "[Alomide eyedrops in the treatment of allergic conjunctivitis and keratoconjunctivitis]."

07/01/1985 - "The efficacy of lodoxamide tromethamine in the treatment of asthma was studied in a 16-week double-blind, placebo-controlled study of 68 perennial allergic subjects with asthma. "
07/01/1985 - "Inhaled lodoxamide tromethamine in the treatment of perennial asthma: a double-blind placebo-controlled study."
07/01/1985 - "Thus, although lodoxamide tromethamine possesses potent mast cell-stabilizing activity in vitro, we have failed to demonstrate any useful long-term effect in the treatment of mild allergic asthma."
06/01/1986 - "A most active biologue of disodium cromoglycate (DSCG) available, lodoxamide tromethamine (LT), has been studied and characterized pharmacologically, in animal and human models of asthma. "
12/01/1981 - "Lodoxamide tromethamine, a new cromolyn-like drug, was studied to determine its effectiveness and duration of action in preventing antigen-induced bronchospasm in 15 subjects with clinically stable extrinsic asthma. "

07/01/1998 - "Clinical studies carried out in 170 patients demonstrated a high efficacy of alomide in the treatment of subacute and chronic pollenosis conjunctivitis, spring keratoconjunctivitis, multiple and toxic allergic keratitis, and other allergic conjunctivities. "

07/01/1998 - "Clinical studies carried out in 170 patients demonstrated a high efficacy of alomide in the treatment of subacute and chronic pollenosis conjunctivitis, spring keratoconjunctivitis, multiple and toxic allergic keratitis, and other allergic conjunctivities. "